221 related articles for article (PubMed ID: 35989659)
21. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
Bhattacharjee S; Sullivan MJ; Wynn RR; Demagall A; Hendrix AS; Sindhwani P; Petros FG; Nadiminty N
BMC Cancer; 2022 Mar; 22(1):312. PubMed ID: 35321693
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
23. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
24. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
[TBL] [Abstract][Full Text] [Related]
25. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
26. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
27. PARP Inhibitors Display Differential Efficacy in Models of
Dickson KA; Xie T; Evenhuis C; Ma Y; Marsh DJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445211
[TBL] [Abstract][Full Text] [Related]
28. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N
Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306
[TBL] [Abstract][Full Text] [Related]
29. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
30. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
[TBL] [Abstract][Full Text] [Related]
31. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
32. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Valabrega G; Scotto G; Tuninetti V; Pani A; Scaglione F
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921561
[TBL] [Abstract][Full Text] [Related]
33. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
[TBL] [Abstract][Full Text] [Related]
34. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
35. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
36. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract][Full Text] [Related]
37. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
38. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
39. Advances in the use of PARP inhibitor therapy for breast cancer.
McCann KE; Hurvitz SA
Drugs Context; 2018; 7():212540. PubMed ID: 30116283
[TBL] [Abstract][Full Text] [Related]
40. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
